Endocyte to Resume Patient Enrollment in PROCEED Phase 3 Trial in U.S.

Endocyte, Inc.

today announced that the FDA has approved the importation of Endocyte's supply of Doxil® from Europe into the U.S. for use in the PROCEED Phase 3 trial. The PROCEED trial was initiated in May 2011 but enrollment stopped later in the year due to global shortages of Doxil. The PROCEED trial compares EC145, in combination with Doxil versus Doxil alone for the treatment of folate-receptor positive platinum resistant ovarian cancer and is designed to repeat the positive final results observed in the PRECEDENT Phase 2 trial in this same patient population. Patients will be imaged with the companion imaging diagnostic, EC20, prior to treatment in order to identify patients whose cancer lesions over-express the folate receptor, the target of EC145.